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ABSTRACT 
INTRODUCTION. 
Isotretinoin treatment has been linked to flares of severe acne, which can be managed 
by the coadministration of systemic corticosteroids or prevented by beginning with a low 
dose of isotretinoin. To our knowledge, there are no estimates in the literature on the 
frequency of coprescription of isotretinoin and systemic corticosteroids. 
OBJECTIVES. 
We sought to quantify the estimated frequency of coprescription of isotretinoin and 
systemic corticosteroids and assess trends of the use of isotretinoin with systemic 
corticosteroids for acne as they relate to age, sex, race, insurance, and provider specialty. 
METHODS.  
Data from the National Ambulatory Medical Care Survey (NAMCS) from 2003 to 2015, 
National Hospital Ambulatory Medical Care Survey Hospital Outpatient Departments 
(NHAMCS-OPD) from 2003 to 2011, and National Hospital Ambulatory Medical Care 
Survey Hospital Emergency Departments (NHAMCS-ED) from 2003 to 2014 were 
aggregated for this analysis. The number of prescriptions for isotretinoin and/or systemic 
corticosteroids was estimated by specialty (for NAMCS) and by survey type (for 
NHAMCS-OPD and NHAMCS-ED). 
RESULTS.  
Among all first visits to a physician for acne (n=18,914,096), approximately 3.9 percent 
prescribed isotretinoin, 0.24 percent prescribed corticosteroids, and the remaining 96 
percent prescribed neither drug. This was comparable to estimates for first visits to a 
dermatologist for acne (n=13,920,913), where approximately 4.2 percent prescribed 
isotretinoin, 0.32 percent prescribed corticosteroids, and the remaining 95 percent 
prescribed neither medication. 
CONCLUSION.  
Currently, isotretinoin and systemic corticosteroids are rarely prescribed together.  
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Acne is a common condition treated by dermatologists and other physicians.1,2 Severe 
acne often requires systemic therapy, such as isotretinoin.1 While isotretinoin is one of 
the most effective treatments for severely inflamed and nodulocystic acne, acne lesions 
can, paradoxically, flare or worsen with initiation of isotretinoin treatment.3 Prescribing 
isotretinoin at a low dose or concurrently prescribing systemic corticosteroids might help 
prevent these flares.1,4 If a flare in acne due to isotretinoin occurs, the concomitant use 
of systemic corticosteroids might help improve skin lesions and, although rare, might 
prevent systemic symptoms associated with acne fulminans.1,3  
To our knowledge, there are no estimates in the literature on the frequency of 
coprescription of isotretinoin and systemic corticosteroids. Given the utility of systemic 
corticosteroids in decreasing acne flares, this study sought to quantify the estimated 
frequency of the coprescribing isotretinoin and systemic corticosteroids. We also aimed 
to assess trends in the use of isotretinoin with systemic corticosteroids for acne as they 
relate to age, sex, race, insurance, and provider specialty. 
METHODS 
Data from the National Ambulatory Medical Care Survey (NAMCS) from 2003 to 2015, 
National Hospital Ambulatory Medical Care Survey Hospital Outpatient Departments 
(NHAMCS-OPD) from 2003 to 2011, and National Hospital Ambulatory Medical Care 
Survey Hospital Emergency Departments (NHAMCS-ED) from 2003 to 2014 were 
aggregated for this analysis.5–9 The number of prescriptions for isotretinoin and/or 
systemic corticosteroids was estimated by specialty (for NAMCS) and by survey type (for 
NHAMCS-OPD and NHAMCS-ED). Visits were stratified and weighted to reflect their 
clustered sampling probability as described by the National Center for Healthcare 
Statistics.10 A visit was considered as being “for acne” if the reason for the visit (or broad 
reason for the visit) listed “acne or pimples” or if the diagnosis listed “acne varioliformis” 
or “other acne.” 
A multivariable logistic regression model for complex samples was used to estimate the 
odds of prescribing isotretinoin during a visit for acne as a function of survey year, age at 
time of visit, sex, race, insurance, and physician specialty. A similar approach was used 
to estimate the odds of prescribing a corticosteroid, though due to too few visits 
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prescribing corticosteroids, survey year and insurance were not considered as covariates 
in the model. Regarding specialty, visits in the emergency department and outpatient 
department datasets were considered as being “nondermatology” visits. 
RESULTS 
Between 2003 and 2015, a total of 97,996,570 visits for acne occurred. Among visits to 
dermatologists for acne (n=58,711,796), approximately 14 percent prescribed 
isotretinoin, 0.53 percent prescribed corticosteroids, and 0.04 percent prescribed both 
isotretinoin and corticosteroids (Figure 1). The remaining 85 percent prescribed neither. 
These estimates differed from visits to nondermatologists for acne (n=39,284,774), where 
2.33 percent prescribed isotretinoin, 0.54 percent prescribed corticosteroids, and zero 
prescribed isotretinoin and corticosteroids. The remaining 97 percent mentioned neither 
drug. 
 
For all first visits to a physician for acne, including dermatologists, (n=18,914,096), 
approximately 3.9 percent prescribed isotretinoin, 0.24 percent prescribed 
corticosteroids, and the remaining 96 percent mentioned neither drug. Among first visits 
to a dermatologist for acne (n=13,920,913), approximately 4.2 percent prescribed 
isotretinoin, 0.32 percent prescribed corticosteroids, and the remaining 95 percent 
mentioned neither medication. In this sample of data, age (p=0.24), race (p=0.39), sex 
(p=0.71), and physician specialty (p=0.90) were not associated with the use of a 
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corticosteroid during a visit for acne (Table 1). Similarly, insurance was not associated 
with the use of isotretinoin. 
 
 
 
 
 
 
 
 
 
Visits to dermatologists were 7.73 times more likely to prescribe isotretinoin than visits to 
nondermatologists (p<0.001) even after controlling for survey year, age, race, sex, and 
insurance (95% confidence interval [CI]: 4.38–13.66). Controlling for all other variables in 
the model, patients between the ages of 20 and 35 years were 1.93 times more likely to 
be prescribed isotretinoin compared with patients older than 35 years (95% CI: 1.27–
2.91, p=0.002), as were patients younger than 20 years of age (OR: 2.75, 95% CI: 1.81–
4.18; p<0.001). Controlling for all other variables in the model, those who identified as 
white were more likely than those who did not identify as white to receive a prescription 
for isotretinoin (OR: 1.65, 95% CI: 1.08–2.53; p=0.01), as were men (OR: 1.50, 95% CI: 
1.10–2.04; p=0.01). 
LIMITATIONS 
The NAMCS does not include medication dosages, acne type, or acne severity, which 
limits inferences in prescribing patterns. Also, there might have been other disorders for 
which the corticosteroid was prescribed at these visits. 
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Conclusion 
The coprescription of isotretinoin and systemic corticosteroids is very rare. These results 
suggest that either many physicians are not experiencing the paradoxical acne flare 
previously reported in the literature,1 are initiating low-dose isotretinoin to minimize the 
risk of a flare, are decreasing the dose of isotretinoin in response to a flare, or are unaware 
of the utility of the coprescription of systemic corticosteroids with isotretinoin. 
Dermatologists are more likely than other specialties to prescribe isotretinoin, which might 
be attributed to the greater severity of acne seen by dermatologists and the level of 
comfort of isotretinoin use developed during specialty training. 
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